At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Market Closed 03-21 16:00:00 EDT
21.08
+0.16
+0.76%
盘后22.46
+1.38+6.52%
19:58 EDT
| High21.41 | Low20.55 | Vol412.58K |
| Open20.64 | D1 Closing20.92 | Amplitude4.10% |
| Mkt Cap1.03B | Tradable Cap567.10M | Total Shares49.00M |
| T/O8.67M | T/O Rate1.53% | Tradable Shares26.90M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03-21 12:02
Enliven Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $39 From $37
THOMSON REUTERS · 03-21 10:09
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million
Reuters · 03-13
Enliven Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03-13
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001’s High Selectivity and Promising Clinical Data
TIPRANKS · 02-04
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. · 2024-12-14
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Enliven Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $42
THOMSON REUTERS · 2024-12-13
Enliven Therapeutics’ ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market
TIPRANKS · 2024-12-10
Promising Market Potential for Enliven Therapeutics’ ELVN-001 in Post-Asciminib CML Treatment Landscape
TIPRANKS · 2024-12-09
Enliven price target raised to $40 from $32 at Baird
TIPRANKS · 2024-11-15
Enliven Therapeutics Inc : Jefferies Raises Target Price to $33 From $32
THOMSON REUTERS · 2024-11-14
Enliven Therapeutics Inc: Current Cash, Cash Equivalents and Marketable Securities Expected to Provide Cash Runway Into Late 2026
THOMSON REUTERS · 2024-11-13
Enliven Therapeutics Q3 Operating Expenses USD 27.068 Million
THOMSON REUTERS · 2024-11-13
Press Release: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Dow Jones · 2024-11-13
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
PR Newswire · 2024-11-07
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
JonesTrading Initiates Enliven Therapeutics at Buy With $36 Price Target
MT Newswires Live · 2024-10-31
Enliven initiated with a Buy at JonesResearch
TIPRANKS · 2024-10-30
TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
TIPRANKS · 2024-09-30
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Enliven Therapeutics (ELVN)
TIPRANKS · 2024-09-30
BRIEF-Enliven Therapeutics Announces Positive Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
Reuters · 2024-09-28
Introduction
Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App